Oxaliplatin-induced acute thrombocytopenia

Erdem G., Dogan M., DEMİRCİ N. S., ZENGİN N.

Journal of Cancer Research and Therapeutics, vol.12, no.2, pp.509-514, 2016 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Review
  • Volume: 12 Issue: 2
  • Publication Date: 2016
  • Doi Number: 10.4103/0973-1482.154056
  • Journal Name: Journal of Cancer Research and Therapeutics
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.509-514
  • Keywords: Drug-induced immune thrombocytopenia, oxaliplatin, thrombocytopenia, IMMUNE-MEDIATED THROMBOCYTOPENIA, OF-THE-LITERATURE, INDUCED HEMOLYTIC-ANEMIA, ADJUVANT TREATMENT, COLON-CANCER, PANCYTOPENIA, PURPURA, FLUOROURACIL, HEMORRHAGE
  • Lokman Hekim University Affiliated: No

Abstract

Oxaliplatin (1, 2-diamminocyclohexaneoxalato-platinum) is a novel platin analog, which is widely used in gastrointestinal malignancies. Platinum analogs damage cellular deoxyribonucleic acid (DNA) by leading covalent bifunctional DNA adducts with cellular DNA. Major side effects of oxaliplatin are neurotoxicity (peripheral neuropathy), myelosuppression with moderate thrombocytopenia and gastrointestinal toxicity (diarrhea). Thrombocytopenia might be related to myelosuppression and/or drug-induced immune thrombocytopenia (DIIT). In here, oxaliplatin-induced thrombocytopenia is discussed with review of the literature.